Caribou Q2 2026 net loss $24.3M; vispa-cel and CB-011 show strong efficacy data

Caribou Biosciences, Inc.

Q2 2026 net loss $24.3M ($0.24/share) vs $54.1M ($0.58) in Q2 2025, which included $21.3M impairment.
Revenue $1.5M vs $2.7M; R&D $18.9M vs $27.7M; G&A $7.9M vs $10.4M.
Cash $113.8M at June 30, 2026, expected to fund operations to end of 2027.
ANTLER data: 82% ORR, 67% CR, 17.1-month median PFS in 2L LBCL (N=27) for vispa-cel.
CB-011 CaMMouflage: 92% ORR, 83% ≥CR, 91% MRD negativity; initial dose expansion data expected H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.